---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-21-000048"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2021-11-03T23:59:59+00:00"
generated_at: "2026-06-28T14:27:48.619904+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics Q3 revenue $125.3M (+74% YoY); FY2021 guidance raised to $490-500M

## Summary
- Revenue $125.3M, up 74% YoY and 8% QoQ; operating loss $15.9M vs $65.3M loss last year.
- Gross margin flat at 80%; net loss $17.2M vs $65.8M loss Q3 2020.
- Cash $600.4M; began shipping Chromium X instrument.
- FY2021 revenue guidance revised to $490-500M (64-67% growth over FY2020).

## SEC filing metadata
- accession: 0001770787-21-000048
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2021-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078721000048/0001770787-21-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078721000048/txg-20211103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-21-000048
- JSON: https://secwatch.observer/filing/0001770787-21-000048.json
- Plain text: https://secwatch.observer/filing/0001770787-21-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.